Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
65.31Enterprise Value over EBITDA
VS
Market
Sector
Industry
History
$ 8.3Close
$ 6.41 - $ 16.8 52-Week Range
Ticker Information
Ticker
GYRECompany Name
GYRE THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQGYRE THERAPEUTICS INC - Enterprise Value over EBITDA Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
GYRE - EV/EBITDA Historical data
| Date | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | Enterprise Value | Enterprise Value over EBITDA |
|---|---|---|---|
| 6/30/2025 | $ 9.86M | $ 643.91M | 65.31 |
| 3/31/2025 | $ 13.36M | $ 880.05M | 65.9 |
| 12/31/2024 | $ 19.63M | $ 1.14B | 58.05 |
| 9/30/2024 | $ -60.39M | $ 1.34B | 0 |
| 6/30/2024 | $ -64.75M | $ 957.47M | 0 |
| 3/31/2024 | $ -72.66M | $ 1.32B | 0 |
| 12/31/2023 | $ -82.99M | $ 1.46B | 0 |
| 9/30/2023 | $ -43.86M | $ 18.24M | 0 |
| 6/30/2023 | $ -47.13M | $ 6.34M | 0 |
| 3/31/2023 | $ 7.04M | $ 208.16K | 0.03 |
Key Performance Insights, Last 5 Years
- GYRE THERAPEUTICS INC's latest trailing twelve months (TTM) EV/EBITDA stands at 0.
- Over the past 5 years, GYRE THERAPEUTICS INC's average EV/EBITDA has been 47.32.
- The median EV/EBITDA for GYRE THERAPEUTICS INC during this period was 61.68
- GYRE THERAPEUTICS INC reached its highest EV/EBITDA over the past 5 years at 65.9.
- The lowest EV/EBITDA recorded by GYRE THERAPEUTICS INC in the same timeframe 0.03
GYRE THERAPEUTICS INC's EV/EBITDA vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
EV/EBITDA Benchmarks
Similar metrics to EV/EBITDA:
- Enterprise Value over EBIT - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest and taxes [EBIT].
- Enterprise Value - [Calculation] Enterprise value (EV) refers to the total value of a business and is frequently used as a more elaborate substitute for market capitalization. EV is calculated as a company's [MarketCap] plus its [Debt] minus cash and cash equivalents [CashnEq].
- Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) - [Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
- Enterprise Value over Free Cash Flow - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its Free Cash Flow [FCF].
Definition of Enterprise Value over EBITDA
[Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].EV / EBITDA
(=) EV/EBITDA EV/EBITDA for GYRE THERAPEUTICS INC is calculated as follows: EV [ $ 104.91M ] / EBITDA [ $ -50.82M ]
(=) EV/EBITDA [ 0 ] GYRE - Enterprise Value over EBITDA, Last 5 years
0.03
Minimum
Mar 31, 2023
65.9
Maximum
Mar 31, 2025
47.32
Average
61.68
Median
EV/EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EV/EBITDA for companies in the Total Stock Market. The average EV/EBITDA of the companies is 13.48 with a standard deviation of 7.65.
The following table provides additional summary stats:
EV/EBITDA in the Market:
| filtered constituents | 2.44K |
|---|---|
| min | 0.01 |
| max | 40.82 |
| average | 13.48 |
| median | 11.75 |
| std | 7.65 |